Publications by authors named "Laura Murta Amaral"
Article Synopsis
- The study evaluates isavuconazole vs. voriconazole for treating suspected invasive aspergillosis (IA) within Brazil's supplementary health system, focusing on cost-effectiveness and budget impact.
- A decision tree model was created, analyzing costs related to drug acquisition, hospitalization, and adverse events over different time horizons, revealing isavuconazole saves 95,174.00 BRL per patient compared to voriconazole.
- The findings indicate that isavuconazole not only outperforms voriconazole in terms of cost-effectiveness and quality of life but also offers significant savings to the health system, estimated at around 20.5 million BRL in the first year and up to 54 million BR
